is a medical device corporation specializing in the ophthalmology sector of the health care industry. LibertyVision
is currently developing and has patented a revolutionary new method to treat exudative macular degeneration or Wet AMD, a disease that currently affects approximately 1.6 million people in the United States alone, and affects over 200,000 new patients each year. This new technology will assist ophthalmologists in better managing patients’ conditions to save their vision.
The primary mission of LibertyVision is the improvement of vision care, with the ultimate goal of providing a better quality of life through patented and patentable advanced eye care technology.